Evidence mapPaperPMID 40563308Full record

ReviewAntioxidants (Basel, Switzerland)2025

Harnessing Antioxidants in Cancer Therapy: Opportunities, Challenges, and Future Directions.

Yu'e Liu, Guangzhen Wu, Linjing Feng, Jialing Li, Yuyang Xia, Wenjia Guo, Kaijun Zhao

Abstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu'e LiuDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID 0009-0007-9516-5017
Guangzhen WuShanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
Linjing FengDepartment of Oncology Surgery, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201800, China.
Jialing LiUniversity of Illinois College of Medicine Rockford Family Medicine, Rockford, IL 61104, USA.
Yuyang XiaSchool of Medicine, I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Wenjia GuoDepartment of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.ORCID 0000-0003-4746-0971
Kaijun ZhaoDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID 0009-0003-3179-4632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antioxidants neutralize reactive oxygen species and free radicals, protecting cells from oxidative damage and maintaining cellular homeostasis. In cancer therapy, they play a complex dual role, serving as protective agents against oxidative stress while, under certain conditions, acting as pro-oxidants that may promote tumorigenesis and resistance to treatment. Redox regulation is governed by key antioxidant pathways, such as the BACH1 and NRF2 pathways, along with transcriptional factors that significantly affect cancer progression and immunotherapy response. In addition to their intracellular effects, antioxidants modulate the tumor microenvironment, including interactions with the extracellular matrix, which impact cancer cell behavior and therapeutic responses. This review also explores preclinical studies that investigate the roles of major antioxidants in cancer biology. While these studies present promising data, significant challenges persist, including the potential for antioxidants to interfere with standard cancer treatments or to inadvertently support tumor survival. We further highlight emerging strategies aimed at optimizing antioxidant therapy, including personalized medicine approaches, nanoparticle-based delivery systems, and combination treatments with immunotherapies and targeted therapies. By examining the therapeutic potential and associated risks of antioxidants, this review provides critical insights into their role in cancer treatment and offers a roadmap for advancing antioxidant-based strategies to improve clinical outcomes.

Indexed as

antioxidantBach1cancer therapyNRF2ROS

Identifiers

PMID40563308
PMCPMC12189842

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.